Skip to content
Screener

Pacific Biosciences of California PACB Business Segments — Sales and marketing

Similar metrics at other companies

Zscaler logo
ZSReportable Segment — Sales and marketing
$295.54M+18.1%
Veeva Systems logo
VEEVReportable Segment — Sales and marketing
$84.19M+14.5%
Lemonade logo
LMNDReportable Segment — Sales and marketing
$11.8M+131%
Yext logo
YEXTReportable Segment — Sales and marketing
$24.87M-21.3%
Dolby Laboratories, Inc. logo
DLBReportable Segment — Sales and marketing
$85.59M+8.8%
Global Business Travel Group logo
GBTGReportable Segment — Sales and marketing
$120M+26.3%

Other financials

Income statement

See full
Revenue$39.0M-1.9%
Gross profit$12.6M-13.9%
Operating income-$44.6M+0.5%
Net income-$44.7M-6.7%
EPS (diluted)-$0.140.0%

Balance sheet

See full
Cash & equivalents$62.6M+10.5%
Total debt$61.8M+17.1%
Total equity-$33.2M-154%
Total assets$751.9M-8.9%

Cash flow

See full
Operating cash flow-$35.6M-21.1%
CapEx$1.6M+183%
Free cash flow-$37.1M-24.1%

Valuation

See full
Market cap$357.46M-5.6%
Enterprise value$356.64M-4.8%
P/S2.2×-0.2×

Profitability

See full
Gross margin36.4%+15.0pp
Operating margin-83.5%-37.4pp
Net margin-82.5%-35.5pp
FCF margin-77.5%-13.2pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio4.9×-2.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.

The source filing: Pacific Biosciences of California’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001299130-26-000122
(In thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Less:
Cost of revenue26,36925,08250,70663,606
Research and development23,02222,52942,63051,582
Sales and marketing18,49219,51634,27039,592
General and administrative14,90116,65930,27636,751
Impairment charges15,000
Settlement charges15,400
Gain on disposal of assets(45,796)

Item 1. Financial Statements (unaudited):

FAQ

What is Pacific Biosciences of California's business segments — sales and marketing?
Pacific Biosciences of California (PACB) reported business segments — sales and marketing of $18.49M in Q2 2026.
How has Pacific Biosciences of California's business segments — sales and marketing changed year-over-year?
Pacific Biosciences of California's business segments — sales and marketing decreased by 5.2% year-over-year, from $19.52M to $18.49M.
What is the long-term trend for Pacific Biosciences of California's business segments — sales and marketing?
Over 3 years (2022 to 2025), Pacific Biosciences of California's business segments — sales and marketing has grown at a -4.8% compound annual growth rate (CAGR), from $84.47M to $72.97M.
What does business segments — sales and marketing mean?
This represents the costs incurred to promote, sell, and distribute the company's sequencing solutions to clinical and research customers. It reflects the company's investment in market penetration, brand awareness, and the effectiveness of its commercial organization.

Ask your AI about Pacific Biosciences of California's business segments — sales and marketing.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude